Insights & Research

A comprehensive guide to essential biomarkers in MASH (NASH) drug discovery. Explore FIB-4, ELF Score, PRO-C3, and MRI-PDFF, and learn how to translate these NITs from animal models to clinical trials.

A comprehensive guide to the Modified Ashcroft Score (Hubner et al., 2008), the gold standard histological scoring system for lung fibrosis models. Learn the 0-8 scale criteria, evaluation tips, and how to combine it with digital quantification.

The distinction between prophylactic and therapeutic dosing in preclinical fibrosis models can determine clinical trial success. We discuss the appropriate dosing timelines across Bleomycin (IPF), GAN diet (MASH), and UUO (renal fibrosis) models, and the lessons from clinical failures of Simtuzumab and Selonsertib.

The Bleomycin pulmonary fibrosis model is the gold standard for IPF drug discovery. We explain solutions to its biggest challenges—"spontaneous resolution" and "variability"—using Micro-Sprayer technology for uniform administration and optimal study design.

There is no 'perfect MASH model.' We explain the importance of the 'Multi-Model Portfolio Strategy'—combining metabolic-focused (GAN) and fibrosis-focused (CDAHFD/CCl4) models—as seen in the development of Semaglutide.

Incorporating in-life liver biopsy into preclinical MASH studies enables paired (intra-individual) analysis, dramatically improving alignment with clinical trial design. We detail the surgical technique, statistical advantages, and AI-powered scoring of biopsy-confirmed study designs.

Prevent 'worked in animals, failed in clinic' in SSc drug development. Compare the 5 major models — Bleomycin, HOCl, Tsk, GVHD, and Fra-2 — from a clinical predictivity perspective, with a target-by-MoA selection guide.

'Skin hardened but lungs didn't improve.' 'Immunotherapy had no effect.' To avoid failures in SSc drug development, we provide a detailed comparison of dosing protocols and evaluation methods for Bleomycin, HOCl, Tsk, and Fra-2 models.